Navigation Links
Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery

Rivaroxaban, a New Oral, Once-Daily Direct Factor Xa Inhibitor, Shows a Significant Reduction in Deep Vein Thrombosis and Pulmonary Embolism Compared with Enoxaparin with Similarly Low Bleeding Rates

GENEVA, July 8, 2007 - Late-breaking Phase III clinical trial data presented today at the XXI International Society on Thrombosis and Haemostasis (ISTH) Congress demonstrate that once-daily rivaroxaban (Xarelto®) achieved superior efficacy in the prevention of venous thromboembolism (VTE) in patients undergoing knee replacement surgery in a head-to-head comparison with enoxaparin, the current standard of care therapy.

Patients in the RECORD3 (REgulation of Coagulation in major Orthopaedic surgery reducing the Risk of DVT and PE) study who were treated with rivaroxaban demonstrated a 49% relative risk reduction (RRR) (p<0.001) of the composite primary endpoint of deep vein thrombosis (DVT), non-fatal pulmonary embolism (PE) and all-cause mortality compared to those treated with enoxaparin. An even greater (62%) reduction of risk (p=0.01) of developing major VTE (the composite of proximal DVT, non-fatal PE and VTE-related death), the secondary endpoint of the trial, was observed in the patients treated with rivaroxaban. Importantly, rivaroxaban also demonstrated a similarly low rate of major bleeding compared to enoxaparin (0.6% and 0.5%, respectively).

Rivaroxaban is an investigational, oral, once-daily direct Factor Xa inhibitor. It is an anticoagulant (a drug designed to prevent and treat blood clots) in advanced clinical development for the prevention and treatment of thrombosis in acute and chronic settings, enabling convenient administration in both the hospital and at home.

Rivaroxaban is being jointly developed by Bayer HealthCare AG and Johnson & Johnson Pharmaceutical Research & Development (J&JPRD), L.L.C.

Lead RECORD3 investigator, Michael R. Lassen
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
Post Your Comments:
(Date:8/29/2014)...  United Therapeutics Corporation (NASDAQ: UTHR ) ... District of New Jersey has ... Sandoz, Inc. regarding United Therapeutics, Remodulin ® product.  In ... U.S. Patent No. 6,765,117 is both valid and enforceable ... generic product until the expiration of that patent in ...
(Date:8/29/2014)... 2014 According to the ... Services (Equipment, Reagent, Primer, Probe, Custom Oligos), End-User ... Gene Synthesis, NGS, DNA, RNAi) - Global Forecast ... Synthesis Market is expected to reach $1,712.1 Million ... at a CAGR of 9.8% from 2014 to ...
(Date:8/29/2014)...  Unilife Corporation ("Unilife" or "Company") (NASDAQ: ... to release its financial results for the fiscal 2014 ... market trading ends on Tuesday, September 9, 2014. ... 4:30 p.m. U.S. EDT on Tuesday, September 9, 2014 ... the Company,s financial results, commercial partnerships, and future outlook.  ...
Breaking Medicine Technology:District Court Decision Received In Remodulin Patent Case 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2
... March 24, 2011 When it comes to their ... to a January 2011 survey by the American Association ... losing their natural teeth. One way to help people ... During Root Canal Awareness Week, March 27 – April ...
... 2011 An educational symposium at the American Academy of ... learn more about the landscape of chronic opioid therapy. ... Opioid Therapy and Risk Management" and sponsored by Ameritox, will ... The event will be held Saturday, March 26 at 5:30 ...
Cached Medicine Technology:Dispelling Myths of Root Canals Through Education 2Symposium Highlights Evolving Landscape of Chronic Opioid Therapy 2
(Date:8/30/2014)... Saturday 30 August 2014: The first recommendations on ... pulmonary embolism are published today in new ESC ... by Professor Stavros V. Konstantinides (Germany/Greece) and Professor ... on the diagnosis and management of acute pulmonary ... Journal (1) and on the ESC Website. , ...
(Date:8/29/2014)... Colorado (PRWEB) August 29, 2014 Daily Gossip ... popular such program on the market nowadays. This method promises ... power, with the use of some effective alternative sources for ... known alternative energy sources are wind and solar power. ... is currently easily accessible in an eBook. So, this is ...
(Date:8/29/2014)... August 30, 2014 Cancer is ... ones and caretakers. Author Eddie M. Leung knows the suffering ... or bile duct cancer, a very rare and aggressive ... Changed My Life” (published by Xlibris), he shares a glimpse ... he imparts a survivor’s testimony that this disease can be ...
(Date:8/29/2014)... Everyone dreams about looking absolutely great, ... , According to the latest review published by Daily ... imagined with the right tips and recommendations. , ... an amazingly effective and fast method of looking perfectly. ... program is really efficient when it comes to the ...
(Date:8/29/2014)... According to this latest review published by DailyGossop.org, this is ... it is amazingly effective. In fact, the program is commonly ... , Driver Robot is so popular, as it can ... highly effective in finding the right drivers that users need ... writes in its Driver Robot review that what users need ...
Breaking Medicine News(10 mins):Health News:First recommendations on all new oral anticoagulants in pulmonary embolism published 2Health News:Home Made Energy Review Exposes Simple Method to Access Alternative Energy Sources 2Health News:Eddie M. Leung Shares His Testimony As a Survivor of Cancer 2Health News:Eddie M. Leung Shares His Testimony As a Survivor of Cancer 3Health News:Shapeshifter Yoga Review Reveals Kris Fondran's New Body Shaping and Fat Loss Program 2Health News:Driver Robot Review Exposes Popular Hardware Detection Tool 2
... Urology (EAU) and Europa Uomo, the European,advocacy movement ... into an,affiliated partnership as part of their long-term ... with regards to urological diseases. Professor Per-Anders Abrahamsson, ... affiliated partnership, Europa Uomo will gain access to ...
... asked to inhibit their response to a "cocaine-cues" video, ... activity in brain regions linked to drug craving, according ... Energy,s Brookhaven National Laboratory. The results, to be published ... that clinical interventions designed to strengthen these inhibitory responses ...
... , ... Old Eats Octopus," gives mealtime tips for raising children who love to eat everything. ... (PRWEB) November 30, 2009 -- ... as a short-order cook at mealtime? Three new short online videos – one focusing ...
... ... and the body in his new book "Healing Heart to Soul: One Doctor’s Journey of ... ... let go of negative emotions, whether caused by us or inflicted by others, can weigh ...
... , Red Cross offers online giving catalog to help families ... Nov. 30 In spite of the economic downturn, Americans are entering ... percent planning to dig deep into their own wallets to support charities ... of buying them a gift, according to a new survey for the ...
... MINNEAPOLIS, Nov. 30 A new study has found that 27% ... intention to shop for and possibly switch their Medicare coverage. ... past four years, the "intention to switch" measure has been a ... with some intention to switch actually will leave their current insurer ...
Cached Medicine News:Health News:Brain scan study shows cocaine abusers can control cravings 2Health News:Brain scan study shows cocaine abusers can control cravings 3Health News:New Videos Help Parents of Picky Eaters 2Health News:New Videos Help Parents of Picky Eaters 3Health News:Healing from the Inside Out: Compelling New Book Explores the Intricate Connection between Body, Soul, and Better Health 2Health News:American Red Cross Survey Finds 62 Percent of Americans Plan to Donate More Than $25 to Charity This Holiday Season in Spite of Economic Downturn 2Health News:American Red Cross Survey Finds 62 Percent of Americans Plan to Donate More Than $25 to Charity This Holiday Season in Spite of Economic Downturn 3Health News:More Seniors Considering Health Insurance Switch 2
... The Professional Gold Package is ... laboratory. The package includes the ... automated system, starter package accessory ... adapter, specimen mounts 1/2" head, ...
... Semi-Automatic Tissue Sectioning System has maintained the ... system. Researchers from around the globe have ... their fresh and fresh fixed tissue sectioning ... With the Vibratome Automatic Tissue Sectioning Systems, ...
... Plus Sectioning System provides a versatile means ... plant tissues. The 1000 employs a ... freezing or embedding. The creation of ... of enzyme activities, and other deleterious effects ...
... with a square vice mounting device. ... for mounting specimens and placing in ... blocks are annodized black for easy ... They are shipped three to ...
Medicine Products: